Compare AbCellera Biologics Inc (ABCL) vs Godaddy Inc (GDDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Godaddy Inc — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Godaddy Inc trades at $87.01 (market cap $11.83B). The key difference: Godaddy Inc is far larger — about 5× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | GDDY | |
|---|---|---|
Market Cap | $2.35B | $11.83B |
Sector | Health | Technology |
52-Week High | $8.12 | $177.04 |
52-Week Low | $2.78 | $75.07 |
Enterprise Value | $1.99B | $14.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
GoDaddy (GDDY) trades at $89.32, up 0.92% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company exhibits strong profitability with a 17.32% net income margin and consistent earnings beats, though revenue growth is moderating. Recent news highlights a securities class action investigation and optimism around AI resilience, with Q2 2026 results due July 30, 2026.
The stock presents a mixed outlook: analyst consensus is bullish with a $123 price target, but legal risks and high ROE from low equity base warrant caution. Upside hinges on execution amid competitive pressures, while any negative legal developments could pressure shares near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
